Your browser is no longer supported. Please, upgrade your browser.
Settings
NMRD Nemaura Medical Inc. daily Stock Chart
NMRD [NASD]
Nemaura Medical Inc.
Index- P/E- EPS (ttm)-0.02 Insider Own67.00% Shs Outstand209.05M Perf Week-4.70%
Market Cap635.51M Forward P/E- EPS next Y- Insider Trans- Shs Float58.97M Perf Month36.32%
Income-2.20M PEG- EPS next Q- Inst Own0.01% Short Float0.09% Perf Quarter13.01%
Sales- P/S- EPS this Y-60.20% Inst Trans-44.74% Short Ratio0.37 Perf Half Y-39.80%
Book/sh0.03 P/B101.33 EPS next Y- ROA-34.00% Target Price- Perf Year-39.80%
Cash/sh0.02 P/C129.70 EPS next 5Y- ROE-52.30% 52W Range2.05 - 6.80 Perf YTD-40.39%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.29% Beta-
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low48.29% ATR0.37
Employees8 Current Ratio4.40 Sales Q/Q- Oper. Margin- RSI (14)60.80 Volatility13.96% 13.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-262.30% Profit Margin- Rel Volume1.64 Prev Close3.10
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume145.76K Price3.04
Recom- SMA2020.54% SMA5025.01% SMA200-19.92% Volume232,837 Change-1.94%
Sep-18-18 08:00AM  Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar GlobeNewswire +5.83%
Sep-13-18 09:19AM  Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday Motley Fool +19.93%
Sep-12-18 08:00AM  Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT® FDA Clinical Trial GlobeNewswire +32.69%
Aug-09-18 08:00AM  Nemaura Medical Inc. Reports First Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 08:00AM  Nemaura Initiates US FDA Studies, and Reports Positive Interim Data from Home-Use Portion of Study GlobeNewswire +6.94%
Jul-17-18 08:00AM  Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch Business Wire +13.53%
Jun-13-18 09:30AM  Nemaura Medical Inc. Reports Full Year Financial Results Business Wire +8.98%
May-30-18 09:30AM  Nemaura Medical Signs Joint Collaboration Agreement for European Commercialization Business Wire
May-15-18 09:30AM  Nemaura Medical to Present at the UBS Global Healthcare Conference Business Wire
Apr-09-18 09:30AM  Nemaura Medical Appoints Bashir Timol Chief Business Officer Business Wire +23.37%
Mar-28-18 11:05AM  Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel Business Wire
Mar-06-18 09:00AM  Nemaura Medical to Ring the Nasdaq Closing Bell Business Wire
Mar-05-18 10:50AM  CORRECTING and REPLACING -- Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
10:00AM  Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Mar-01-18 04:18PM  Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch Business Wire
Feb-09-18 01:17PM  Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results Business Wire
Jan-31-18 01:20PM  Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program Business Wire +7.24%
Jan-23-18 09:00AM  Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018 Business Wire +6.38%
Dec-21-17 10:00AM  Nemaura Announces Completion of SugarBEAT® European Clinical Trial Programme and Positive Interim Results Business Wire
Dec-06-17 09:00AM  Nemaura Announces Successful SugarBEAT® Interim Precision Study Results Business Wire
Nov-02-17 09:47AM  Nemaura Medical Inc. Reports Second Quarter 2017 Financial Results Business Wire
Sep-26-17 09:00AM  WallStreet Research Announces Availability of Corporate Profile Coverage on Nemaura Medical, Inc. Business Wire
Sep-21-17 09:00AM  Nemaura Announces Successful Interim Results for SugarBEAT® European Clinical Trials Business Wire
Aug-29-17 11:24AM  Nemaura Develops Medical Grade SugarBEAT® Android App for Diabetes Management Business Wire
Aug-15-17 12:47PM  Nemaura Signs Heads of Terms for sugarBEAT® with Device Technologies for Australia and New Zealand Business Wire
Aug-09-17 09:00AM  Nemaura Medical Inc. Reports First Quarter 2017 Financial Results Business Wire
Aug-03-17 09:00AM  Nemaura Appoints Thomas Moore to Board of Directors as Independent Director Business Wire -14.58%
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes specialty medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. The company was founded in 2009 and is headquartered in Loughborough, the United Kingdom.